Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 8, 2012, Pages 2034-2042

  Pea, Federico ^a   Viale, Pierluigi ^b   Cojutti, Piergiorgio ^a   Del pin, Barbara ^b   Zamparini, Eleonora ^b   Furlanut, Mario ^a  

^a SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

TDM; Therapy; Thrombocytopenia

Indexed keywords

AMIODARONE; AMLODIPINE; LINEZOLID; OMEPRAZOLE; RIFAMPICIN;

ADULT; ANEMIA; ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL ARTHRITIS; BONE AND JOINT INFECTIONS; BRAIN ABSCESS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLACTATEMIA; LIVER ABSCESS; LONG TERM CARE; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; NOCARDIOSIS; PROSTHESIS INFECTION; PSEUDARTHROSIS; RETROSPECTIVE STUDY; SKIN ALLERGY; SKIN INFECTION; SOFT TISSUE INFECTION; SPONDYLITIS; THROMBOCYTOPENIA; TREATMENT DURATION; VISUAL DISORDER; WOUND INFECTION;

ACETAMIDES; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; DRUG MONITORING; DRUG TOXICITY; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; PLASMA; RETROSPECTIVE STUDIES; RIFAMPIN; TREATMENT OUTCOME;

EID: 84864509183     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks153     Document Type: Article

References (42)

1. Woodford N, Livermore DM. Infections caused by Gram-positive bacteria: a review of the global challenge. J Infect 2009; 59 Suppl 1: S4-16.
2. Vinh DC, Rubinstein E. Linezolid: a review of safety and tolerability. J Infect 2009; 59 Suppl 1: S59-74.
3. Dong H, Wang X, Dong Y et al. Clinical pharmacokinetic/ pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 2011; 38: 296-300.
4. Lovering AM, Le Floch R, Hovsepian L et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 2009; 63: 553-9.
5. Bolhuis MS, van Altena R, Uges DR et al. Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 2010; 54: 5418-9.
6. Pea F, Furlanut M, Cojutti P et al. Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis. Antimicrob Agents Chemother 2010; 54: 4605-10.
7. Gandelman K, Zhu T, Fahmi OA et al. Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 2010; 51: 229-36.
8. Swoboda S, Ober MC, Lichtenstern C et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010; 66: 291-8.
9. Caminero JA, Sotgiu G, Zumla A et al. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis 2010; 10: 621-9.
10. Moylett EH, Pacheco SE, Brown-Elliott BA et al. Clinical experience with linezolid for the treatment of nocardia infection. Clin Infect Dis 2003; 36: 313-8.
11. Legout L, Valette M, Dezeque H et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? J Antimicrob Chemother 2010; 65: 2224-30.
12. Papadopoulos A, Plachouras D, Giannitsioti E et al. Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study. J Chemother 2009; 21: 165-9.
13. Egle H, Trittler R, Kummerer K et al. Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 2005; 77: 451-3.
14. Lacarelle B, Pisano P, Gauthier T et al. Abbott PKS system: a new version for applied pharmacokinetics including Bayesian estimation. Int J Biomed Comput 1994; 36: 127-30.
15. Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 2003; 42: 1129-40.
16. Islinger F, Dehghanyar P, Sauermann R et al. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents 2006; 27: 108-12.
17. Peng GW, Stryd RP, Murata S et al. Determination of linezolid in plasma by reversed-phase high-performance liquid chromatography. J Pharm Biomed Anal 1999; 20: 65-73.
18. Pea F, Viale P, Lugano M et al. Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases. Am J Kidney Dis 2004; 44: 1097-102.
19. Takahashi Y, Takesue Y, Nakajima K et al. Risk factors associated with the development of thrombocytopenia in patients who received linezolid therapy. J Infect Chemother 2011; 17: 382-7.
20. Pauli-Magnus C, Rekersbrink S, Klotz U et al. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001; 364: 551-7.
21. Haslam IS, Jones K, Coleman T et al. Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cells. Br J Pharmacol 2008; 154: 246-55.
22. Gebhart BC, Barker BC, Markewitz BA. Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 2007; 27: 476-9.
23. Soriano A, Ortega M, Garcia S et al. Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 2007; 51: 2559-63.
24. Soriano A, Miro O, Mensa J. Mitochondrial toxicity associated with linezolid. N Engl J Med 2005; 353: 2305-6.
25. Renslo AR. Antibacterial oxazolidinones: emerging structure-toxicity relationships. Expert Rev Anti Infect Ther 2010; 8: 565-74.
26. McKee EE, Ferguson M, Bentley AT et al. Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones. Antimicrob Agents Chemother 2006; 50: 2042-9.
27. Stein GE, Wells EM. The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid. Curr Med Res Opin 2010; 26: 571-88.
28. Myrianthefs P, Markantonis SL, Vlachos K et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother 2006; 50: 3971-6.
29. Pea F, Viale P, Lugano M et al. Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients. J Antimicrob Chemother 2009; 63: 167-9.
30. Lovering AM, Zhang J, Bannister GC et al. Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement. J Antimicrob Chemother 2002; 50: 73-7.
31. Tsuji Y, Hiraki Y, Matsumoto K et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 2010; 17: 70-5.
32. Matsumoto K, Takeshita A, Ikawa K et al. Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction. Int J Antimicrob Agents 2010; 36: 179-81.
33. Hiraki Y, Tsuji Y, Hiraike M et al. Correlation between serum linezolid concentration and the development of thrombocytopenia. Scand J Infect Dis 2012; 44: 60-4.
34. Jones RN, Fritsche TR, Sader HS et al. Zyvox Annual Appraisal of Potency and Spectrum Program Results for 2006: an activity and spectrum analysis of linezolid using clinical isolates from 16 countries. Diagn Microbiol Infect Dis 2007; 59: 199-209.
35. Rayner CR, Forrest A, Meagher AK et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23.
36. Gomez J, Canovas E, Banos V et al. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother 2011; 55: 4308-10.
37. Senneville E, Legout L, Valette M et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28: 1155-63.
38. Vergidis P, Rouse MS, Euba G et al. Treatment with linezolid or vancomycin in combination with rifampin is effective in an animal model of methicillin-resistant Staphylococcus aureus foreign body osteomyelitis. Antimicrob Agents Chemother 2011; 55: 1182-6.
39. Baldoni D, Haschke M, Rajacic Z et al. Linezolid alone or combined with rifampin against methicillin-resistant Staphylococcus aureus in experimental foreign-body infection. Antimicrob Agents Chemother 2009; 53: 1142-8.
40. Murillo O, Domenech A, Euba G et al. Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. J Infect 2008; 57: 229-35.
41. Miller K, O'Neill AJ, Wilcox MH et al. Delayed development of linezolid resistance in Staphylococcus aureus following exposure to low levels of antimicrobial agents. Antimicrob Agents Chemother 2008; 52: 1940-4.
42. Hellmark B, Unemo M, Nilsdotter-Augustinsson A et al. In vitro antimicrobial synergy testing of coagulase-negative staphylococci isolated from prosthetic joint infections using Etest and with a focus on rifampicin and linezolid. Eur J Clin Microbiol Infect Dis 2010; 29: 591-5.